Bufotenin is a naturally occurring tryptamine compound structurally similar to serotonin, psilocin, and DMT. It is known chemically as 5-hydroxy-N,N-dimethyltryptamine (5-HO-DMT). Bufotenin is found in certain toads (notably Bufo alvarius), as well as in the seeds of Anadenanthera peregrina and Virola trees. It has been used for centuries by South American tribes in shamanic rituals and is studied today for its psychoactive, neurological, and anthropological properties.

• Chemical Structure: Bufotenin belongs to the tryptamine family, characterized by an indole ring and ethylamine side chain, similar to neurotransmitters like serotonin.

• Biological Presence: Naturally produced in small amounts in humans and animals; its presence has been detected in cerebrospinal fluid and urine.

• Historical Use: Indigenous cultures in the Amazon used bufotenin-containing snuffs such as Yopo for spiritual and divinatory practices.

• Modern Relevance: Bufotenin is being researched for its potential insights into human consciousness, receptor binding properties, and entheogenic effects.

• Mechanism of Action: It acts primarily on 5-HT2A serotonin receptors, which are implicated in visual and sensory processing, mood, and cognition.

• Subjective Effects: Often includes intense visuals, bodily sensations (like facial flushing or pressure), and altered states of perception.

• Legal Classification: Bufotenin is a controlled substance in many countries, including the U.S. (Schedule I), due to its hallucinogenic effects despite limited evidence of abuse potential.

The legality of bufotenin varies significantly depending on the country or region. It is often classified as a controlled substance due to its psychoactive properties, even when derived from natural sources. Researchers must be cautious when acquiring or studying it, ensuring compliance with national and international regulations.

• United States: Classified as a Schedule I substance under the Controlled Substances Act, making it illegal to possess or distribute without DEA authorization.

• Canada: Bufotenin is not specifically scheduled, but it may fall under analog provisions depending on usage.

• Europe: Many European countries consider bufotenin illegal, though some tolerate its use in research or traditional contexts.

• South America: In regions where Anadenanthera trees grow, cultural exemptions may exist for indigenous ceremonial use.

• Legal Grey Areas: In some jurisdictions, the natural sources (e.g., seeds or toad secretions) may be legal while the isolated compound is not.

• Research Exemptions: Academic or scientific researchers may be permitted to handle bufotenin with proper licenses and institutional oversight.

• Buyer Responsibility: At Psycho Plug, we advise all customers to verify bufotenin’s legal status in their country before placing an order to avoid legal complications.

Bufotenin’s effects are intense, short-acting, and highly visual. It is known for producing profound changes in perception, cognition, and bodily sensation. The experience can vary significantly depending on the dose, method of administration, individual physiology, and set and setting.

• Visual Hallucinations: Includes fractal patterns, light trails, and color shifts; similar to DMT or psilocybin but often with a more tactile component.

• Somatic Sensations: Users frequently report strong physical feelings like facial flushing, chest pressure, and internal vibrations or tingling.

• Altered Perception: May include time dilation, spatial disorientation, and a sense of detachment or merging with surroundings.

• Cognitive Changes: Thoughts may become nonlinear, abstract, or metaphysical, and users may experience temporary ego dissolution.

• Intensity: The effects can onset within minutes and reach a peak quickly, often within 5–15 minutes of administration.

• Emotional Responses: Mood swings can occur; experiences may be euphoric, insightful, or overwhelming depending on mental state.

• Aftereffects: Users often feel physically drained or mentally contemplative for a few hours after the effects wear off.

Proper storage of bufotenin is critical to preserving its stability, potency, and safety for research use. As a sensitive compound, bufotenin can degrade when exposed to heat, light, or moisture. Following best storage practices ensures a longer shelf life and consistent experimental results.

• Temperature: Store in a cool environment, ideally between 2°C and 8°C (refrigerated), away from any heat sources.

• Humidity Control: Keep in a dry, airtight container to prevent moisture degradation or mold formation.

• Light Protection: Use amber or opaque containers to shield the compound from UV light, which can break down molecular structure.

• Air Exposure: Limit exposure to oxygen by using sealed vials with minimal headspace and, optionally, inert gas blankets.

• Labeling: Clearly mark containers with the compound name, batch number, and date of receipt for traceability.

• Contamination Prevention: Use sterile tools to handle the compound to avoid introducing contaminants that may alter purity.

• Shelf Life: Under proper storage, bufotenin remains stable for up to 24 months. Always check for discoloration or odors before use.

Bufotenin dosage varies based on the intended experimental protocol, administration route, and study goals. Since it is a powerful psychedelic, even small amounts can produce significant effects. All handling and application should be carried out by qualified researchers in controlled environments.

• Low Dose Range: Between 2–5 mg, suitable for threshold studies or receptor affinity testing.

• Common Dose Range: 8–15 mg is typical for observing psychoactive and visual effects under monitored lab conditions.

• High Dose Range: 20–30 mg may produce very intense effects and should only be used with caution and full safety protocols.

• Route of Administration: Dosage needs vary between vaporization, insufflation, and oral ingestion; vaporization typically requires less compound.

• Body Weight Consideration: Some research suggests effects scale with body mass; adjust dose accordingly for accurate modeling.

• Titration Recommended: Begin with a low dose and titrate upwards to determine minimum effective quantities for your study.

• Purity Factor: Ensure you’re accounting for actual bufotenin content (≥99%) when measuring doses; impure compounds require recalibration.

Bufotenin is offered strictly for laboratory research and analytical study. Personal or recreational use is not endorsed by Psycho Plug and may be illegal in many jurisdictions. While bufotenin has a long history of ceremonial use, its modern classification and safety profile demand responsible, controlled handling.

• Legal Restrictions: In most countries, personal use of bufotenin is prohibited due to its classification as a Schedule I or equivalent substance.

• Health Risks: Unsupervised use can pose psychological and physiological risks, especially at higher doses or in uncontrolled environments.

• Research-Only Sale: Our bufotenin is not intended, labeled, or sold for human consumption or personal experimentation.

• Lack of Standardized Dosing: Without clinical guidance or dosing guidelines, personal use risks include overdose or extreme psychological reactions.

• Potential for Adverse Effects: Panic attacks, elevated heart rate, and anxiety are possible, especially in untrained or sensitive individuals.

• Liability Waiver: Purchasers must acknowledge that the product is for research purposes only and accept responsibility for lawful handling.

• Ethical Concerns: Using a powerful entheogen recreationally without context, safety measures, or integration may lead to misuse and misunderstanding of the compound’s effects.

Bufotenin can be administered using several methods, each yielding different onset times and intensity profiles. The route of administration plays a critical role in bioavailability, duration, and overall subjective effects observed in studies. All administration must follow ethical research protocols and safety standards.

• Vaporization: Heating bufotenin to its sublimation point without combustion is one of the most common research methods. Effects onset rapidly (within 2–5 minutes).

• Insufflation: Snorting finely powdered bufotenin leads to quicker absorption through mucosal membranes. This method was traditional in Yopo rituals but may cause nasal discomfort.

• Oral Ingestion: Orally consumed bufotenin is less bioavailable and may require an MAOI (monoamine oxidase inhibitor) to activate, increasing risks and complexities.

• Sublingual/Buccal: Placing the substance under the tongue or against the cheek may provide modest effects, but absorption efficiency varies.

• Injection (Animal Studies): In preclinical settings, bufotenin may be administered intraperitoneally or intravenously to lab animals for receptor binding or neurological studies.

• Inhalation of Snuff: Ethnobotanical studies often involve powdered Anadenanthera seeds (containing bufotenin) administered via nasal insufflation by shamans.

• Dosage Precision: Regardless of method, accurate milligram-scale dosing is essential. Researchers typically use microgram-sensitive balances to avoid errors.

Bufotenin’s side effects are well-documented, especially when taken in larger-than-recommended quantities. While many of its effects are sought after for research into altered consciousness, the compound can also provoke discomfort and physiological responses that must be managed carefully.

• Facial Flushing: One of the most consistent physical reactions, caused by vasodilation of blood vessels near the skin.

• Chest Pressure or Tightness: May occur shortly after administration; generally non-dangerous but can be alarming to inexperienced subjects.

• Nausea: Especially common when bufotenin is ingested orally. This can interfere with study variables and subject well-being.

• Anxiety or Panic: The intense nature of bufotenin’s effects may trigger acute psychological reactions, particularly in anxious or unprepared individuals.

• Cardiovascular Response: Elevated heart rate and blood pressure may occur; those with heart conditions should never be exposed to the compound.

• Motor Disturbance: Muscle tension or temporary physical disorientation can happen during peak effects.

• Aftereffects: Some participants report fatigue, mental fog, or emotional sensitivity for a few hours post-experience.

Current scientific understanding suggests that bufotenin is not physically addictive. Unlike substances that cause repeated dopaminergic reinforcement (such as opioids or stimulants), bufotenin does not create chemical dependency. However, psychological factors and repeated use should be approached with caution.

• Non-Rewarding Pharmacology: Bufotenin does not strongly activate reward centers in the brain, making habitual use less likely.

• No Physical Withdrawal: There are no documented withdrawal symptoms associated with cessation of bufotenin use.

• Rapid Tolerance Buildup: Tolerance develops quickly, requiring longer intervals between sessions to maintain the same intensity—this naturally discourages overuse.

• Low Abuse Potential: Most users do not describe bufotenin as compulsively enjoyable; its intensity and side effects often act as deterrents.

• Psychological Curiosity: While not addictive in the classic sense, some individuals may pursue repeat experiences seeking further insights or altered states.

• Legal Classification Considerations: Bufotenin’s placement in Schedule I may be influenced more by its effects than abuse statistics.

• Harm Reduction: Any repeated use—even in research—should be guided by ethical review and an understanding of mental health risks.

Combining bufotenin with other substances, particularly psychedelics or MAOIs, introduces significant risks and is not recommended without extensive pharmacological planning and institutional oversight. Such combinations can result in intensified effects or dangerous physiological reactions.

• With MAOIs: Monoamine oxidase inhibitors can potentiate bufotenin when taken orally, but they also drastically increase the risk of serotonin syndrome, hypertension, or death.

• With Other Psychedelics: Combining bufotenin with LSD, psilocybin, or DMT may lead to unpredictable synergistic effects, overwhelming the subject and increasing psychological risk.

• With Stimulants: Pairing bufotenin with amphetamines or caffeine may strain the cardiovascular system and amplify anxiety or panic.

• With Alcohol: Alcohol’s depressant effects conflict with bufotenin’s stimulating properties, possibly causing nausea, dehydration, or loss of motor control.

• Pharmacological Complexity: Bufotenin interacts with multiple serotonin receptors, and combining it with other compounds may alter binding affinity or duration.

• Research-Only Context: Psycho Plug supplies bufotenin for isolated study. We do not support poly-substance research unless under qualified, ethically approved programs.

• Controlled Conditions Only: Any study involving substance combinations must be conducted in licensed labs with full medical supervision.

The effects of bufotenin are generally short in duration compared to other psychedelics, but they can be extremely intense within that time frame. The length of the experience depends heavily on the route of administration, dosage, individual metabolism, and environmental context. In most research contexts, the short action profile of bufotenin is considered advantageous for acute observational studies.

• Vaporized Bufotenin: Onset occurs within 1–3 minutes, with peak effects lasting 15–30 minutes and full dissipation around 60–90 minutes.

• Insufflated Bufotenin: Onset ranges from 5–10 minutes, with effects lasting between 45–90 minutes depending on dose and individual tolerance.

• Oral Bufotenin (with MAOI): Without an MAOI, oral bufotenin is typically inactive or very mild. When paired with an MAOI, effects may last 2–3 hours but carry additional health risks.

• Peak Window: Most users report that the peak intensity is concentrated within the first 10–30 minutes after administration, followed by a gradual taper.

• Aftereffects: Mild psychological afterglow, introspection, or fatigue may persist for several hours after the main effects subside.

• Metabolic Rate Impact: Faster metabolisms tend to reduce the duration, while slower metabolisms or impaired liver function may extend the effects.

• Clear Termination: Unlike some psychedelics that fade gradually, bufotenin’s effects often conclude sharply, returning the user to baseline quickly.

Yes, bufotenin can pose risks if used in excessively high doses or in unsafe settings. While it has a relatively low toxicity compared to many synthetic drugs, its effects on the cardiovascular system and central nervous system mean that overdose is a serious concern, particularly in unsupervised environments.

• Narrow Safety Margin: Bufotenin’s effective dose is relatively close to the dose that can produce unwanted or dangerous side effects, especially via insufflation or vaporization.

• Cardiovascular Distress: High doses can cause rapid heart rate, blood pressure spikes, and intense vasodilation, leading to physical discomfort or danger in sensitive individuals.

• Psychological Overload: Large doses can trigger terrifying hallucinations, confusion, or loss of control, which can lead to panic or self-injury.

• Respiratory Reaction: In rare cases, bufotenin may cause shortness of breath, particularly if the powder is not properly vaporized or is inhaled improperly.

• Toxicological Reports: While human fatalities from bufotenin are extremely rare, animal studies show dose-dependent toxicity at high thresholds.

• Interaction Risk: Combining bufotenin with MAOIs or serotonin-affecting drugs significantly raises the risk of serotonin syndrome, a potentially fatal condition.

• Safe Research Practices: Always begin with microdoses in controlled settings and use analytical-grade scales to avoid dosing errors.

At Psycho Plug, we supply bufotenin that exceeds 99% purity, verified by advanced analytical techniques such as Gas Chromatography-Mass Spectrometry (GC-MS) and High-Performance Liquid Chromatography (HPLC). Purity is critical to ensuring that research outcomes are consistent, replicable, and free from contaminants that could skew results or pose safety hazards.

• ≥99% Assay Guarantee: Each batch is lab-verified to be at least 99% pure, ensuring minimal by-products or synthesis residues.

• Test Methodology: Purity is assessed using GC-MS and HPLC, which are industry-standard for compound identity and contaminant detection.

• Batch Control: Every order of bufotenin is traceable to a specific batch ID, allowing for transparency and quality control tracking.

• No Fillers or Additives: Our bufotenin contains no binding agents, cutting substances, or stabilizers—it is pure active compound only.

• Consistency Across Batches: Strict production protocols ensure uniform purity levels across all inventory cycles.

• Storage-Dependent Stability: Purity is preserved through temperature-controlled storage from lab to customer.

• Documentation Available: Certificates of Analysis (CoA) and purity reports are available upon request with any order.

Yes, Psycho Plug provides Certificates of Analysis (CoAs) for every batch of bufotenin upon request. These documents verify the identity, purity, and analytical parameters of the compound, giving researchers confidence in their materials and compliance with institutional review protocols.

• Full Lab Reports: CoAs include chemical identity confirmation, purity percentage, testing method, batch number, and date of analysis.

• Independent Lab Verification: Analyses are conducted by certified third-party labs or in-house facilities with ISO/GLP compliance.

• Batch-Specific Documentation: CoAs are linked to each specific production batch, ensuring traceability and accountability.

• Request Process: Simply contact our support team with your order number to receive the corresponding CoA in PDF format.

• Regulatory Use: CoAs support documentation requirements for academic research, import/export processes, and institutional oversight.

• Transparency Policy: We believe in full transparency, providing customers with data that validate the chemical integrity of our products.

• No Extra Charge: CoAs are included at no additional cost—ensuring every customer receives verifiable data.

Yes, every order placed with Psycho Plug is assigned a unique tracking number upon shipment. We partner with secure logistics providers to ensure real-time tracking visibility and peace of mind throughout the delivery process. Discretion and speed are prioritized at every step.

• Instant Tracking Activation: Once your package ships (usually within 24 hours), you will receive an email with your tracking link.

• 24/7 Monitoring: Track your shipment in real time from our facility to your doorstep via secure courier portals.

• Discreet Packaging: While tracking is enabled, packages contain no identifying labels, logos, or product names.

• Delivery Estimates: Domestic shipments often arrive overnight or within 2 business days; international orders vary by destination.

• Reshipment Policy: If tracking shows a delivery issue (e.g., lost or held in customs), our team will initiate a refund or replacement.

• Customer Service Support: If tracking stalls or fails to update, we provide direct support and contact with our logistics partners.

• Proof of Delivery: Upon completion, carriers typically provide photographic or signature-based confirmation for secure handoff.